However, this data requires further confirmation and extension to impaired cytotoxic activity against specific target cells, e.g., impaired killing of B-cell maturation antigen (BCMA) expressing myeloma cells by antiBCMA-specific CAR-T cells. Here, TNFRSF17 is linked to plasma cell myeloma.